Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there. Did your doctor somehow miss the recovery protocol that Pedro Bach-y-Rita used to recover fully back in 1958 with only a partial brain?

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, November 18, 2026

Growth hormone as a treatment for post-stroke recovery: a review of preclinical and clinical evidence

Let's check how long your stroke medical 'professionals' have been incompetent in not creating protocols for your recovery using this! Someone in that decade should have fired all these people that are not solving stroke!

 Growth hormone as a treatment for post-stroke recovery: a review of
preclinical and clinical evidence

Emmanuelle Zakheim, Daniel Moon, Wesley Tran, Ephrem Gerald and Mohamed Ahmed*
Department of Basic Sciences, College of Medicine, California Northstate University, West Taron
Drive, Elk Grove, CA 95757 USA
* Correspondence: Email: mohamed.ahmed@cnsu.edu.

Abstract: 


Despite advances in acute stroke management, many survivors experience lasting motor
and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are wellestablished, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors,
memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post -
stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis
following brain injury. This review aims to summarize GH’s proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as
an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies
that examined GH administration following ischemic stroke was conducted, emphasizing functional,
cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling,
synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies
demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and
associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and
angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II
COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional
independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer,
Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS),
National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls,
without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and
safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive

recovery; however, existing clinical trials are small and varied in design, and larger, multicenter
randomized controlled trials are required to establish optimal dosing, timing, and treatment duration
before GH can be incorporated into standard post-stroke care.

No comments:

Post a Comment